Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
Cancer
    April 2024
  1. AJABNOOR AM, Parisi R, Zghebi SS, Ashcroft DM, et al
    Oral anticoagulant prescribing among patients with cancer and atrial fibrillation in England, 2009-2019.
    Cancer. 2024;130:1316-1329.
    >> Share

    March 2024
  2. VITA E, Monaca F, Milardi D, Mastrantoni L, et al
    Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK-positive advanced nonsmall cell lung cancer.
    Cancer. 2024 Mar 28. doi: 10.1002/cncr.35293.
    >> Share

  3. WISNIVESKY JP, Mudd J, Stone K, Slatore CG, et al
    Longitudinal quality of life after sublobar resection and stereotactic body radiation therapy for early-stage non-small cell lung cancer.
    Cancer. 2024 Mar 21. doi: 10.1002/cncr.35286.
    >> Share

  4. CITTOLIN-SANTOS GF, Knapp B, Ganesh B, Gao F, et al
    The changing landscape of small cell lung cancer.
    Cancer. 2024 Mar 12. doi: 10.1002/cncr.35281.
    >> Share

  5. NIERENGARTEN MB
    Updated American Cancer Society lung cancer screening guidelines: The new guidelines offer expanded criteria recommended for lung cancer screening based on age, smoking status, and smoking history.
    Cancer. 2024;130:656-657.
    >> Share

  6. WEST HJ, Pennell NA
    Lessons from ADAURA: Can we improve on a positive trial?
    Cancer. 2024;130:659-664.
    >> Share

    February 2024
  7. TAN AC, Lai GGY, Saw SPL, Chua KLM, et al
    Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
    Cancer. 2024 Feb 29. doi: 10.1002/cncr.35263.
    >> Share

  8. MORGENSZTERN D
    The expanding role of circulating tumor DNA in resectable non-small cell lung cancer.
    Cancer. 2024 Feb 29. doi: 10.1002/cncr.35268.
    >> Share


  9. Erratum to "Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of >/=50%: The EMPOWER-Lung 1 study".
    Cancer. 2024 Feb 23. doi: 10.1002/cncr.35165.
    >> Share

  10. NIERENGARTEN MB
    Phase 3 AEGEAN trial results show the benefit of perioperative immunotherapy-based treatment for NSCLC.
    Cancer. 2024;130:495-496.
    >> Share

  11. DESAI A, Smith CJ, Pritchett JC, Leventakos K, et al
    Examining crossover and postprotocol therapies in first-line immunotherapy trials in non-small cell lung cancer (NSCLC).
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35250.
    >> Share

  12. ZHOU Y, Guo T, Liang F, Wang Z, et al
    Cumulative incidence and risk factors of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35242.
    >> Share

  13. RUSSELL AM, Pack AP, Bailey SC, Weldon CB, et al
    A local perspective on internal, external, and reflexive biomarker testing processes for lung cancer in an academic medical center.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35240.
    >> Share

    January 2024
  14. IOCOLANO M, Yegya-Raman N, Friedes C, Wang X, et al
    Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era.
    Cancer. 2024 Jan 31. doi: 10.1002/cncr.35230.
    >> Share

  15. FLOREZ N, Kaufman RA, Yanez-Sarmiento A, Abioye O, et al
    When the unimaginable happens: Lung cancer diagnosis during pregnancy.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35227.
    >> Share

  16. KRATZER TB, Bandi P, Freedman ND, Smith RA, et al
    Lung cancer statistics, 2023.
    Cancer. 2024 Jan 27. doi: 10.1002/cncr.35128.
    >> Share

  17. ROLFO C, Del Re M, Russo A
    Exploring the epigenetic susceptibility mechanisms of lung cancer through DNA methylation markers.
    Cancer. 2024 Jan 18. doi: 10.1002/cncr.35203.
    >> Share

  18. HONG J, Lee J, Park S, Jung HA, et al
    Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B.
    Cancer. 2024 Jan 2. doi: 10.1002/cncr.35175.
    >> Share

  19. MEZA R, Cao P, de Nijs K, Jeon J, et al
    Assessing the impact of increasing lung screening eligibility by relaxing the maximum years-since-quit threshold: A simulation modeling study.
    Cancer. 2024;130:244-255.
    >> Share

    December 2023
  20. TRAN TN, Lee S, Kim HJ, Lee Y, et al
    Treatment-related cardiovascular events in patients with non-small cell lung cancer: Evidence from real-world data with a competing risks approach.
    Cancer. 2023 Dec 16. doi: 10.1002/cncr.35143.
    >> Share

  21. WANG S, Xie T, Li Y, Guo L, et al
    Low TP53 variant allele frequency as a biomarker for anti-programmed death (ligand) 1 monotherapy in lung adenocarcinoma.
    Cancer. 2023;129:3873-3883.
    >> Share

  22. ZHAO X, Yang M, Fan J, Wang M, et al
    Identification of genetically predicted DNA methylation markers associated with non-small cell lung cancer risk among 34,964 cases and 448,579 controls.
    Cancer. 2023 Dec 6. doi: 10.1002/cncr.35130.
    >> Share


  23. Immunotherapy plus stereotactic radiation therapy improves event-free survival in early-stage non-small cell lung cancer.
    Cancer. 2023;129:3680.
    >> Share

    November 2023
  24. GUAN MC, Ding Q, Ning J, Zhu H, et al
    Metformin as a booster or obstacle of immunotherapy in patients with non-small cell lung cancer and diabetes mellitus.
    Cancer. 2023 Nov 21. doi: 10.1002/cncr.35111.
    >> Share

  25. LESHEM Y, Dolev Y, Siegelmann-Danieli N, Sharman Moser S, et al
    Reply to "Metformin as a booster or obstacle of immunotherapy in patients with non-small cell lung cancer and diabetes mellitus".
    Cancer. 2023 Nov 21. doi: 10.1002/cncr.35134.
    >> Share

  26. GRIESINGER F, Ramagopalan S, Cheung WY, Wilke T, et al
    Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databases.
    Cancer. 2023 Nov 7. doi: 10.1002/cncr.35094.
    >> Share

  27. LANDY R, Cheung LC, Young CD, Chaturvedi AK, et al
    Absolute lung cancer risk increases among individuals with >15 quit-years: Analyses to inform the update of the American Cancer Society lung cancer screening guidelines.
    Cancer. 2023 Nov 1. doi: 10.1002/cncr.34758.
    >> Share

  28. HENDRICK RE, Smith RA
    Benefit-to-radiation-risk of low-dose computed tomography lung cancer screening.
    Cancer. 2023 Nov 1. doi: 10.1002/cncr.34855.
    >> Share

    October 2023
  29. VAN VEGGEL BAMH, van der Wekken AJ, Paats MS, Hendriks LEL, et al
    A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancer.
    Cancer. 2023 Oct 31. doi: 10.1002/cncr.35090.
    >> Share

  30. MAHAR AL, Biggs K, Hansford RL, Derksen S, et al
    Stage IV breast, colorectal, and lung cancer at diagnosis in adults living with intellectual or developmental disabilities: A population-based cross-sectional study.
    Cancer. 2023 Oct 30. doi: 10.1002/cncr.35068.
    >> Share

  31. CHOI E, Luo SJ, Ding VY, Wu JT, et al
    Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model.
    Cancer. 2023 Oct 25. doi: 10.1002/cncr.35069.
    >> Share

  32. PARK S, Kim YJ, Min YJ, Mortimer PGS, et al
    Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
    Cancer. 2023 Oct 16. doi: 10.1002/cncr.35059.
    >> Share

  33. FLOREZ N, Kiel L, Meza K, Wei Z, et al
    Sexual Health Assessment in Women with Lung Cancer study: Sexual health assessment in women with lung cancer.
    Cancer. 2023 Oct 16. doi: 10.1002/cncr.35057.
    >> Share

  34. VAN TUIJL LA, Basten M, Pan KY, Vermeulen R, et al
    Depression, anxiety, and the risk of cancer: An individual participant data meta-analysis.
    Cancer. 2023;129:3287-3299.
    >> Share


  35. Erratum to "JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer".
    Cancer. 2023 Oct 13. doi: 10.1002/cncr.35064.
    >> Share

  36. TAMMEMAGI MC, Cina K, Kitts AKB, Koop D, et al
    Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self-reporting as Indigenous and non-Indigenous.
    Cancer. 2023 Oct 9. doi: 10.1002/cncr.34947.
    >> Share

  37. NIERENGARTEN MB
    Stopping immunotherapy after 2 years is practical in patients with advanced non-small cell lung cancer.
    Cancer. 2023;129:2925-2926.
    >> Share

    September 2023
  38. PINSKY PF, Osarogiagbon R
    Diagnostic follow-up of indeterminate pulmonary nodules in the Medicare population.
    Cancer. 2023;129:2808-2816.
    >> Share

  39. LU S, Guo X, Li Y, Liu H, et al
    Antiprogrammed death ligand 1 therapy failed to reduce the risk of developing brain metastases in patients with extensive-stage small cell lung cancer: A retrospective analysis.
    Cancer. 2023 Sep 8. doi: 10.1002/cncr.35003.
    >> Share

  40. TAMMEMAGI MC
    Time to quit using quit time as a lung cancer screening eligibility criterion.
    Cancer. 2023 Sep 1. doi: 10.1002/cncr.34999.
    >> Share

    August 2023
  41. CARLISLE JW, Leal T
    Advancing immunotherapy in small cell lung cancer.
    Cancer. 2023 Aug 21. doi: 10.1002/cncr.34977.
    >> Share

  42. NIERENGARTEN MB
    Overall lung cancer screening rates low.
    Cancer. 2023;129:2440.
    >> Share

  43. SEBASTIAN NT, Webb A, Shilo K, Robb R, et al
    A PI3K gene expression signature predicts for recurrence in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy (SBRT).
    Cancer. 2023 Aug 10. doi: 10.1002/cncr.34983.
    >> Share

  44. AGARWAL M, Liu A, Almquist D, Langlais BT, et al
    Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status.
    Cancer. 2023 Aug 7. doi: 10.1002/cncr.34966.
    >> Share

  45. BOYLE TA, Bossler AD
    RNA sequencing steps toward the first line.
    Cancer. 2023;129:2294-2296.
    >> Share

    July 2023
  46. BERGER Y, Gadiraju M, Dhiman A, Gilliam K, et al
    Surgical phenotype of patients with peritoneal mesothelioma and a germline mutation.
    Cancer. 2023;129:2152-2160.
    >> Share

  47. COLAMONICI M, Khouzam N, Dell C, Auge-Bronersky K, et al
    Promoting lung cancer screening of high-risk patients by primary care providers.
    Cancer. 2023 Jul 14. doi: 10.1002/cncr.34955.
    >> Share

    June 2023
  48. MCCALL NS, Janopaul-Naylor JR, McGinnis HS, Kesarwala AH, et al
    Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer.
    Cancer. 2023 Jun 24. doi: 10.1002/cncr.34915.
    >> Share

  49. LESHEM Y, Dolev Y, Siegelmann-Danieli N, Sharman Moser S, et al
    Association between diabetes mellitus and reduced efficacy of pembrolizumab in non-small cell lung cancer.
    Cancer. 2023 Jun 24. doi: 10.1002/cncr.34918.
    >> Share

  50. ZHOU Q, Zhao J, Chang J, Wang H, et al
    Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer.
    Cancer. 2023 Jun 6. doi: 10.1002/cncr.34897.
    >> Share

  51. NIERENGARTEN MB
    Risk model-based lung cancer screening.
    Cancer. 2023;129:1628.
    >> Share

  52. NIERENGARTEN MB
    Adherence to evidence-based surgical metrics improves outcomes in lung cancer.
    Cancer. 2023;129:1627.
    >> Share

  53. DESAI A, Reddy NK, Subbiah V
    Top advances of the year: Precision oncology.
    Cancer. 2023;129:1634-1642.
    >> Share

  54. GHIAUR G, Valkenburg KC, Esteb C, Ambinder A, et al
    Bone marrow niche chemoprotection of metastatic solid tumors mediated by CYP3A4.
    Cancer. 2023;129:1744-1751.
    >> Share

    May 2023
  55. WANG C, Chang Y, Ren J, Wu Z, et al
    Modifiable risk-attributable and age-related burden of lung cancer in China, 1990-2019.
    Cancer. 2023 May 23. doi: 10.1002/cncr.34850.
    >> Share

  56. KIDANE B, Gerard IJ, Spicer J, Kim JO, et al
    Stereotactic Ablative radiotherapy before resection to avoid delay for early-stage lung cancer or oligometastases during the COVID-19 pandemic: Pathologic outcomes from the SABR-BRIDGE protocol.
    Cancer. 2023 May 23. doi: 10.1002/cncr.34880.
    >> Share

  57. MAKHARADZE T, Quek RGW, Melkadze T, Gogishvili M, et al
    Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
    Cancer. 2023 May 8. doi: 10.1002/cncr.34687.
    >> Share

  58. ALTAN M, Tu J, Milton DR, Yilmaz B, et al
    Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.
    Cancer. 2023 May 2. doi: 10.1002/cncr.34820.
    >> Share

    April 2023
  59. JU S, Cui Z, Hong Y, Wang X, et al
    Detection of multiple types of cancer driver mutations using targeted RNA sequencing in nonsmall cell lung cancer.
    Cancer. 2023 Apr 25. doi: 10.1002/cncr.34804.
    >> Share

  60. HERRERA-JUAREZ M, Serrano-Gomez C, Bote-de-Cabo H, Paz-Ares L, et al
    Targeted therapy for lung cancer: Beyond EGFR and ALK.
    Cancer. 2023 Apr 19. doi: 10.1002/cncr.34757.
    >> Share

  61. EBERTH JM, Gieske MR, Silvestri GA
    Changing recommendations for lung cancer screening: National Lung Cancer Roundtable member perspectives.
    Cancer. 2023 Apr 14. doi: 10.1002/cncr.34798.
    >> Share

  62. NAKAHAMA K, Izumi M, Yoshimoto N, Fukui M, et al
    Vimentin expression correlates with immune-checkpoint inhibitor efficacy in non-small cell lung cancer.
    Cancer. 2023 Apr 6. doi: 10.1002/cncr.34782.
    >> Share

  63. NIERENGARTEN MB
    First person profile: Yi-Long Wu, MD: Dr Wu's research has progressed from improving the survival rates of patients with non-small cell lung cancer and is now focused on ensuring that he and the next generation of researchers can find a cure.: Dr Wu's
    Cancer. 2023;129:978-979.
    >> Share

    March 2023
  64. WU Y, Verma V, Gay CM, Chen Y, et al
    Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis.
    Cancer. 2023 Mar 30. doi: 10.1002/cncr.34755.
    >> Share

  65. ERNANI V, Appiah AK, Rodriguez D, Kusne Y, et al
    Lobar versus sublobar resection for atypical lung carcinoid: An analysis from the National Cancer Database.
    Cancer. 2023;129:860-866.
    >> Share

  66. BIRONZO P, Cani M, Jacobs F, Napoli VM, et al
    Real-world retrospective study of KRAS mutations in advanced nonsmall cell lung cancer in the era of immunotherapy.
    Cancer. 2023 Mar 11. doi: 10.1002/cncr.34731.
    >> Share

    February 2023
  67. VILLARUZ LC, Blumenschein GR Jr, Otterson GA, Leal TA, et al
    Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.
    Cancer. 2023 Feb 27. doi: 10.1002/cncr.34683.
    >> Share

  68. HE J, Ma P, Zhao D, Shi X, et al
    Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: A dose-escalation phase 1 study.
    Cancer. 2023 Feb 22. doi: 10.1002/cncr.34697.
    >> Share

  69. NELSON AT, Harris AK, Watson D, Miniati D, et al
    Type I and Ir pleuropulmonary blastoma (PPB): A report from the International PPB/DICER1 Registry.
    Cancer. 2023;129:600-613.
    >> Share

  70. PENG Y, Zhao Q, Liao Z, Ma Y, et al
    Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
    Cancer. 2023 Feb 7. doi: 10.1002/cncr.34664.
    >> Share

    December 2022
  71. CRONIN KA, Scott S, Firth AU, Sung H, et al
    Annual report to the nation on the status of cancer, part 1: National cancer statistics.
    Cancer. 2022;128:4251-4284.
    >> Share

  72. DE MIGUEL-PEREZ D, Russo A, Gunasekaran M, Buemi F, et al
    Baseline extracellular vesicle TGF-beta is a predictive biomarker for response to immune-checkpoint inhibitors and survival in non-small-cell lung cancer.
    Cancer. 2022 Dec 9. doi: 10.1002/cncr.34576.
    >> Share


  73. First-line combined therapy improves metastatic non-small cell lung cancer survival regardless of mutational status.
    Cancer. 2022;128:4039.
    >> Share

    November 2022
  74. LEE Y, Kim HR, Hong MH, Lee KH, et al
    A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation.
    Cancer. 2022 Nov 30. doi: 10.1002/cncr.34553.
    >> Share

  75. SALOUS T, Shukla NA, Althouse SK, Perkins SM, et al
    A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.
    Cancer. 2022 Nov 24. doi: 10.1002/cncr.34565.
    >> Share

  76. ZHOU T, Zhang Y, Ma Y, Ma W, et al
    Comparison of aprepitant versus desloratadine for EGFR-TKI-induced pruritus: A randomized phase 2 clinical trial.
    Cancer. 2022;128:3969-3976.
    >> Share

  77. GOGEBAKAN KC, Lange J, Slatore CG, Etzioni R, et al
    Modeling the impact of novel systemic treatments on lung cancer screening benefits.
    Cancer. 2022 Nov 1. doi: 10.1002/cncr.34527.
    >> Share

    October 2022
  78. GUMUS M, Chen CI, Ivanescu C, Kilickap S, et al
    Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of >/=50%: The EMPOWER-Lung 1 study.
    Cancer. 2022 Oct 29. doi: 10.1002/cncr.34477.
    >> Share


  79. Adagrasib shines in a lung cancer trial.
    Cancer. 2022;128:3432-3433.
    >> Share

  80. PATEL AV, Deubler E, Teras LR, Colditz GA, et al
    Key risk factors for the relative and absolute 5-year risk of cancer to enhance cancer screening and prevention.
    Cancer. 2022;128:3502-3515.
    >> Share

  81. COLONNA M, Grosclaude P, Bouvier AM, Goungounga J, et al
    Health status of prevalent cancer cases as measured by mortality dynamics (cancer vs. noncancer): Application to five major cancers sites.
    Cancer. 2022;128:3663-3673.
    >> Share

    September 2022

  82. Emphysema linked to increased risk of lung cancer.
    Cancer. 2022;128:3277.
    >> Share

  83. SNYDER RA, Hu CY, DiBrito SR, Chang GJ, et al
    Association of Medicaid expansion with racial disparities in cancer stage at presentation.
    Cancer. 2022;128:3340-3351.
    >> Share

  84. PANG LL, Gan JD, Tan JR, Huang YH, et al
    Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I.
    Cancer. 2022 Sep 7. doi: 10.1002/cncr.34451.
    >> Share

  85. O'ROURKE K
    First person profile: Thomas Lynch Jr, MD: Dr Lynch's focus on enabling success makes him an impactful lung cancer specialist, physician-scientist, and physician-executive: Dr Lynch's focus on enabling success makes him an impactful lung cancer specia
    Cancer. 2022;128.
    >> Share

    August 2022
  86. O'ROURKE K
    Lung cancer screening associated with earlier diagnosis and improved survival.
    Cancer. 2022;128:3011-3012.
    >> Share

  87. MOHINDRA NA, Patel JD
    Top advances in lung cancer, 2021.
    Cancer. 2022 Aug 10. doi: 10.1002/cncr.34406.
    >> Share

    July 2022
  88. BATTAGLIA TA, Gunn CM, Bak SM, Flacks J, et al
    Patient navigation to address sociolegal barriers for patients with cancer: A comparative-effectiveness study.
    Cancer. 2022;128 Suppl 13:2623-2635.
    >> Share

    June 2022
  89. ZABLOTSKA LB, Lane RSD, Randhawa K
    Association between exposures to radon and gamma-ray radiation and histologic type of lung cancer in Eldorado uranium mining and milling workers from Canada.
    Cancer. 2022 Jun 29. doi: 10.1002/cncr.34351.
    >> Share

  90. PETRILLO LA, Shimer SE, Zhou AZ, Sommer RK, et al
    Prognostic communication about lung cancer in the precision oncology era: A multiple-perspective qualitative study.
    Cancer. 2022 Jun 22. doi: 10.1002/cncr.34369.
    >> Share

  91. CORTELLINI A, Ricciuti B, Borghaei H, Naqash AR, et al
    Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
    Cancer. 2022 Jun 21. doi: 10.1002/cncr.34348.
    >> Share

  92. WARNER ET
    Race, place, and socioeconomic status: A path toward lung cancer early detection.
    Cancer. 2022 Jun 20. doi: 10.1002/cncr.34330.
    >> Share

  93. GUPTA A, Omeogu CH, Islam JY, Joshi AR, et al
    Association of area-level socioeconomic status and non-small cell lung cancer stage by race/ethnicity and health care-level factors: Analysis of the National Cancer Database.
    Cancer. 2022 Jun 20. doi: 10.1002/cncr.34327.
    >> Share

  94. JOUNG RH, Nelson H, Mullett TW, Kurtzman SH, et al
    A national quality improvement study identifying and addressing cancer screening deficits due to the COVID-19 pandemic.
    Cancer. 2022;128:2119-2125.
    >> Share

  95. YOO JE, Han K, Shin DW, Jung W, et al
    Effect of smoking reduction, cessation, and resumption on cancer risk: A nationwide cohort study.
    Cancer. 2022;128:2126-2137.
    >> Share

    May 2022
  96. NAITO T, Uchino J, Kojima T, Matano Y, et al
    A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index.
    Cancer. 2022;128:2025-2035.
    >> Share

  97. O'ROURKE K
    Blood test helps predict who might benefit from lung cancer screening: A recent study examining a test based on a combination of a blood test and a risk prediction model shows that it is more sensitive than current risk prediction criteria.: A recent
    Cancer. 2022;128:1721-1722.
    >> Share

    April 2022
  98. SHESHADRI A, Goizueta AA, Shannon VR, London D, et al
    Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study.
    Cancer. 2022 Apr 22. doi: 10.1002/cncr.34229.
    >> Share

  99. EZE C, Guggenberger JE, Schmidt-Hegemann NS, Kenndoff S, et al
    Pooled analysis on image-guided moderately hypofractionated thoracic irradiation in inoperable node-positive/recurrent patients with non-small cell lung cancer with poor prognostic factors and severely limited pulmonary function and reserve.
    Cancer. 2022 Apr 13. doi: 10.1002/cncr.34201.
    >> Share

    March 2022
  100. O'ROURKE K
    Trastuzumab deruxtecan shows durable activity in HER2-mutant non-small cell lung cancer.
    Cancer. 2022;128:938.
    >> Share

    February 2022
  101. WILLIAMS RM, Li T, Luta G, Wang MQ, et al
    Lung cancer screening use and implications of varying eligibility criteria by race and ethnicity: 2019 Behavioral Risk Factor Surveillance System data.
    Cancer. 2022 Feb 24. doi: 10.1002/cncr.34098.
    >> Share

  102. PAZ-ARES L, Spigel DR, Chen Y, Jove M, et al
    RESILIENT part 1: A phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.
    Cancer. 2022 Feb 23. doi: 10.1002/cncr.34123.
    >> Share

  103. LI N, Wang BX, Li J, Shao Y, et al
    Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
    Cancer. 2022;128:708-718.
    >> Share

  104. SAHAR L, Douangchai Wills VL, Liu KKA, Fedewa SA, et al
    Geographic access to lung cancer screening among eligible adults living in rural and urban environments in the United States.
    Cancer. 2022 Feb 15. doi: 10.1002/cncr.33996.
    >> Share

  105. LOWENSTEIN LM, Nishi SPE, Lopez-Olivo MA, Crocker LC, et al
    Smoking cessation services and shared decision-making practices among lung cancer screening facilities: A cross-sectional study.
    Cancer. 2022 Feb 14. doi: 10.1002/cncr.34145.
    >> Share

  106. WILLIAMS RM, Cordon M, Eyestone E, Smith L, et al
    Improved motivation and readiness to quit shortly after lung cancer screening: Evidence for a teachable moment.
    Cancer. 2022 Feb 10. doi: 10.1002/cncr.34133.
    >> Share

    January 2022
  107. TJOKROWIDJAJA A, Lord SJ, John T, Lewis CR, et al
    Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer.
    Cancer. 2022 Jan 28. doi: 10.1002/cncr.34113.
    >> Share

  108. KNEUERTZ PJ, Abdel-Rasoul M, D'Souza DM, Zhao J, et al
    Segmentectomy for clinical stage I non-small cell lung cancer: National benchmarks for nodal staging and outcomes by operative approach.
    Cancer. 2022 Jan 7. doi: 10.1002/cncr.34071.
    >> Share

  109. NOONE AM, Pfeiffer RM, Schaubel DE, Dorgan JF, et al
    Life-years lost due to cancer among solid organ transplant recipients in the United States, 1987 to 2014.
    Cancer. 2022;128:150-159.
    >> Share

    November 2021
  110. JAVIER-DESLOGES J, Nelson TJ, Murphy JD, McKay RR, et al
    Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials.
    Cancer. 2021 Nov 22. doi: 10.1002/cncr.33991.
    >> Share

  111. HAY A
    Adjuvant trials suggest changes to non-small cell lung cancer treatment paradigm: Results from clinical trials presented at the 2021 annual meeting of the American Society of Clinical Oncology may point to new ways to improve individualized therapy.
    Cancer. 2021;127:4121-4122.
    >> Share

    October 2021
  112. KIM H, Kim DW, Kim M, Lee Y, et al
    Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world d
    Cancer. 2021 Oct 27. doi: 10.1002/cncr.33984.
    >> Share

    September 2021
  113. RAMALINGAM SS, Thara E, Awad MM, Dowlati A, et al
    JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
    Cancer. 2021 Sep 3. doi: 10.1002/cncr.33885.
    >> Share

    August 2021
  114. KOBAYASHI M, Kako J, Kajiwara K, Ogata A, et al
    The effects of curative-intent cancer therapy on employment, work ability, and work limitations.
    Cancer. 2021;127:3031-3032.
    >> Share

  115. TEVAARWERK AJ, Kwekkeboom K, Buhr KA, Dennee A, et al
    Reply to The effects of curative-intent cancer therapy on employment, work ability, and work limitations.
    Cancer. 2021;127:3033-3034.
    >> Share

  116. GOULD MK
    Personalized lung cancer screening: Are we ready to ENGAGE?
    Cancer. 2021 Aug 12. doi: 10.1002/cncr.33839.
    >> Share

  117. TOUMAZIS I, Alagoz O, Leung A, Plevritis SK, et al
    A risk-based framework for assessing real-time lung cancer screening eligibility that incorporates life expectancy and past screening findings.
    Cancer. 2021 Aug 12. doi: 10.1002/cncr.33835.
    >> Share

  118. PRINTZ C
    First person profile: John D. Minna, MD: This renowned lung cancer researcher continues pioneering treatments, inspiring his colleagues and trainees.
    Cancer. 2021;127:2605-2606.
    >> Share

  119. RECKAMP KL, Behrendt CE, Slavin TP, Gray SW, et al
    Germline mutations and age at onset of lung adenocarcinoma.
    Cancer. 2021;127:2801-2806.
    >> Share

    July 2021
  120. PRINTZ C
    New findings show disparities in lung cancer care and research.
    Cancer. 2021;127:2173.
    >> Share

    May 2021
  121. HAJDU SI
    Pathfinders in oncology from the time the causal relation between tobacco use and lung cancer was established to publication of the first Cancer Staging Manual by the American Joint Committee on Cancer.
    Cancer. 2021 May 10. doi: 10.1002/cncr.33561.
    >> Share

    April 2021
  122. KHURI FR
    From Cancer to COVID, Boston to Beirut.
    Cancer. 2021;127:1172-1173.
    >> Share

  123. PARK S, Olsen S, Ku BM, Lee MS, et al
    High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean lung liquid versus invasive biopsy program.
    Cancer. 2021 Apr 7. doi: 10.1002/cncr.33571.
    >> Share

  124. HU ZI, Ghafoor A, Sengupta M, Hassan R, et al
    Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies.
    Cancer. 2021;127:1010-1020.
    >> Share

    February 2021
  125. NABI J, Tully KH, Cole AP, Marchese M, et al
    Access denied: The relationship between patient insurance status and access to high-volume hospitals.
    Cancer. 2021;127:577-585.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016